Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects

Pharmacol Res. 2022 Feb:176:106064. doi: 10.1016/j.phrs.2022.106064. Epub 2022 Jan 6.
No abstract available

Keywords: Drug resistance; Genotype; Human immunodeficiency virus type 1; Leronlimab; Maraviroc; Phenotype.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Antibodies, Monoclonal, Humanized / pharmacology*
  • Cells, Cultured
  • Drug Resistance, Viral
  • HIV Antibodies / pharmacology*
  • HIV Infections / drug therapy
  • HIV-1 / drug effects*
  • Humans
  • Maraviroc / therapeutic use
  • Receptors, CCR5

Substances

  • Anti-HIV Agents
  • Antibodies, Monoclonal, Humanized
  • HIV Antibodies
  • Receptors, CCR5
  • Maraviroc
  • leronlimab

Associated data

  • ClinicalTrials.gov/NCT04098315